Cost-effectiveness analysis: A tool in the hands of the clinician

Abstract

Get full access to this article

View all access options for this article.

References

Christensen CM, Grossman JH and Hwang J. The Innovator's Prescription: A Disruptive Solution for Health Care. New York: McGraw-Hill, 2009, p. 441.

Kraal

Van den Akker-Van Marle

Abu-Hanna

et al.

Clinical and cost-effectiveness of home-based cardiac rehabilitation compared to conventional, centre-based cardiac rehabilitation: Results of the FIT@Home study. Eur J Prev Cardiol 2017; 24: 1260–1273.

Frederix

Solmi

Piepoli

et al.

Cardiac telerehabilitation: A novel cost-efficient care delivery strategy that can induce long-term health benefits. Eur J Prev Cardiol 2017; 24: 1708–1717.

Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. Epub ahead of print 8 November 2018. DOI: 10.1016/j.jacc.2018.11.003.

Eikelboom

Connolly

Bosch

et al.

Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017; 377: 1319–1330.

Anand

Bosch

Eikelboom

et al.

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: An international, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391: 219–229.

Aboyans

Braekkan

Mazzolai

et al.

The year 2017 in cardiology: Aorta and peripheral circulation. Eur Heart J 2018; 39: 730–738.

De Carlo

Aboyans

. The re-birth of an ESC Working Group. Eur Heart J 2018; 39: 725–726.

Zomer

Hird

et al.

Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective. Eur J Prev Cardiol. 2019; 26: 858–868.

10.

Lopez-Lopez

Sterne

JAC

Thom

HHZ

et al.

Oral anticoagulants for prevention of stroke in atrial fibrillation: Systematic review, network meta-analysis, and cost effectiveness analysis. BMJ 2017; 359: j5058–j5058.

11.

Ademi

Zomer

Tonkin

et al.

Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective. Int J Cardiol 2018; 270: 54–59.